Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Wang F, Xiang Z, Huang T, Zhang M, Zhou WB. ANLN directly interacts with RhoA to promote doxorubicin resistance in breast cancer cells. Cancer Manage Res. 2020;12:9725–34. https://doi.org/10.2147/CMAR.S261828.

Article  CAS  Google Scholar 

Wang Z, Zhang M, Shan R, Wang YJ, Chen J, Huang J, Sun LQ, Zhou WB. MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells. Oncol Rep. 2019;42:1915–23. https://doi.org/10.3892/or.2019.7292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Xiang Z, Wang F, Shan R, Li L, Chen J, Liu BA, Huang J, Sun LQ, Zhou WB. STARD4 promotes breast cancer cell malignancy. Oncol Rep. 2020;44:2487–502. https://doi.org/10.3892/or.2020.7802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181–204. https://doi.org/10.1146/annurev-pathol-042420-093238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Tang H, Chen Y, Chen Z, Hu Z, Cui Z, Tao Y, Yuan J, Fu Y, Zhuang Z, He Q, Li Q, Xu X, Wan X, Jiang Y, Mao Z. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat Cancer. 2023;4:716–33. https://doi.org/10.1038/s43018-023-00535-w.

Article  CAS  PubMed  Google Scholar 

Bassiouni R, Idowu MO, Gibbs LD, Robila V, Grizzard PJ, Webb MG, Song J, Noriega A, Craig DW, Carpten JD. Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. Cancer Res. 2023;83:34–48. https://doi.org/10.1158/0008-5472.CAN-22-2682.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113. https://doi.org/10.1038/s41571-021-00565-2.

Article  CAS  PubMed  Google Scholar 

Shiao SL, Gouin KH 3rd, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, Ben-Cheikh B, Henson R, Mita M, McAndrew P, Karlan S, Giuliano A, Chung A, Amersi F, Dang C, Richardson H, Shon W, Dadmanesh F, Burnison M, Mirhadi A, Zumsteg ZS, Choi R, Davis M, Lee J, Rollins D, Martin C, Khameneh NH, McArthur H, Knott SRV. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42(70–84):e78. https://doi.org/10.1016/j.ccell.2023.12.012.

Article  CAS  Google Scholar 

Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P, Memon FH, Kim KH, Kang IS, Choi KH. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408. https://doi.org/10.1016/j.biopha.2023.114408.

Article  CAS  PubMed  Google Scholar 

Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–86. https://doi.org/10.1007/978-1-4939-3378-5_21.

Article  CAS  PubMed  Google Scholar 

Liu J, Zhang M, Sun Q, Qin X, Gao T, Xu Y, Han S, Zhang Y, Guo Z. Construction of a novel MPT-driven necrosis-related lncRNAs signature for prognosis prediction in laryngeal squamous cell carcinoma. Environ Sci Pollut Res Int. 2023. https://doi.org/10.1007/s11356-023-26996-1.

Article  PubMed  PubMed Central  Google Scholar 

Xu Z, Zhang M, Guo Z, Chen L, Yang X, Li X, Liang Q, Tang Y, Liu J. Stemness-related lncRNAs signature as a biologic prognostic model for head and neck squamous cell carcinoma. Apoptosis. 2023. https://doi.org/10.1007/s10495-023-01832-6.

Article  PubMed  PubMed Central  Google Scholar 

Zhang M, Wang F, Xiang Z, Huang T, Zhou WB. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp Pharmacol Physiol. 2020;47:1464–72. https://doi.org/10.1111/1440-1681.13307.

Article  CAS  PubMed  Google Scholar 

Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol. 2010;220:126–39. https://doi.org/10.1002/path.2638.

Article  CAS  PubMed  Google Scholar 

Zuo Y, Li Y, Zhou Z, Ma M, Fu K. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother. 2017;95:922–8. https://doi.org/10.1016/j.biopha.2017.09.005.

Article  CAS  PubMed  Google Scholar 

Wang L, Liu D, Wu X, Zeng Y, Li L, Hou Y, Li W, Liu Z. Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): expression analysis and biological roles research. J Cell Physiol. 2018;233:6603–12. https://doi.org/10.1002/jcp.26311.

Article  CAS  PubMed  Google Scholar 

Niu L, Fan Q, Yan M, Wang L. LncRNA NRON down-regulates lncRNA snaR and inhibits cancer cell proliferation in TNBC. 2019. Biosci Rep. https://doi.org/10.1042/BSR20190468.

Chen FY, Zhou ZY, Zhang KJ, Pang J, Wang SM. Long non-coding RNA MIR100HG promotes the migration, invasion and proliferation of triple-negative breast cancer cells by targeting the miR-5590-3p/OTX1 axis. Cancer Cell Int. 2020;20:508. https://doi.org/10.1186/s12935-020-01580-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang G, Gao L, Zhang J, Wang R, Wei X. Long non-coding RNA PTCSC3 suppresses triple-negative breast cancer by downregulating long non-coding RNA MIR100HG. Oncol Lett. 2023;26:331. https://doi.org/10.3892/ol.2023.13917.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Luan T, Zhou S, Lin J, Yang Y, Liu W, Tong X, Jiang W. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Cancer Med. 2019;8:4389–403. https://doi.org/10.1002/cam4.2335.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo N, Zhang K, Li X, Hu Y. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA. J Cell Biochem. 2020;121:4176–87. https://doi.org/10.1002/jcb.29572.

Article  CAS  PubMed  Google Scholar 

Castro-Oropeza R, Melendez-Zajgla J, Maldonado V, Vazquez-Santillan K. The emerging role of lncRNAs in the regulation of cancer stem cells. Cell Oncol. 2018;41:585–603. https://doi.org/10.1007/s13402-018-0406-4.

Article  Google Scholar 

McCabe EM, Rasmussen TP. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer Biol. 2021;75:38–48. https://doi.org/10.1016/j.semcancer.2020.12.012.

Article  CAS  PubMed  Google Scholar 

He Y, Jiang X, Duan L, Xiong Q, Yuan Y, Liu P, Jiang L, Shen Q, Zhao S, Yang C, Chen Y. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol Cancer. 2021;20:156. https://doi.org/10.1186/s12943-021-01469-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Wang W, Wu M, Zhu P, Zhou Z, Gong Y, Gu Y. LncRNA LINC01315 silencing modulates cancer stem cell properties and epithelial-to-mesenchymal transition in colorectal cancer via miR-484/DLK1 axis. Cell Cycle. 2022;21:851–73. https://doi.org/10.1080/15384101.2022.2033415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cruickshank BM, Wasson MD, Brown JM, Fernando W, Venkatesh J, Walker OL, Morales-Quintanilla F, Dahn ML, Vidovic D, Dean CA, VanIderstine C, Dellaire G, Marcato P. LncRNA PART1 promotes proliferation and migration, is associated with cancer stem cells, and alters the miRNA landscape in triple-negative breast cancer. Cancers. 2021. https://doi.org/10.3390/cancers13112644.

Article  PubMed  PubMed Central  Google Scholar 

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(338–354):e315. https://doi.org/10.1016/j.cell.2018.03.034.

Article  CAS  Google Scholar 

Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, Mudge JM, Sisu C, Wright J, Armstrong J, Barnes I, Berry A, Bignell A, Carbonell Sala S, Chrast J, Cunningham F, Di Domenico T, Donaldson S, Fiddes IT, García Girón C, Gonzalez JM, Grego T, Hardy M, Hourlier T, Hunt T, Izuogu OG, Lagarde J, Martin FJ, Martínez L, Mohanan S, Muir P, Navarro FCP, Parker A, Pei B, Pozo F, Ruffier M, Schmitt BM, Stapleton E, Suner MM, Sycheva I, Uszczynska-Ratajczak B, Xu J, Yates A, Zerbino D, Zhang Y, Aken B, Choudhary JS, Gerstein M, Guigó R, Hubbard TJP, Kellis M, Paten B, Reymond A, Tress ML, Flicek P. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766-d773. https://doi.org/10.1093/nar/gky955.

Article  CAS  PubMed  Google Scholar 

Sun Q, Qin X, Zhao J, Gao T, Xu Y, Chen G, Bai G, Guo Z, Liu J. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma. Apoptosis. 2022. https://doi.org/10.1007/s10495-022-01790-5.

Article  PubMed  PubMed Central